Authors
Latest:
Lilian Gien, MD, Talks Next Steps for Immunotherapy Research in Recurrent Clear Cell Carcinoma of the OvaryLillian Gien, MD, spoke about continued use of immunotherapy in patients with recurrent clear cell carcinoma of the ovary following results of a trial examining pembrolizumab plus epacadostat.
Latest:
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood CancerRahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Latest:
A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A MutationJohnathan Q. Trinh, MD, et al discuss a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor.
Latest:
Looking Ahead in the Multiple Myeloma Treatment LandscapeExperts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
Latest:
Relapsed/Refractory Multiple Myeloma: Practice Pearls and Future Directions in CareThomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, share closing thoughts on the evolving landscape of cytokine release syndrome management in relapsed/refractory multiple myeloma.
Latest:
Radiation Therapy in Diffuse Large B-Cell Lymphoma: A Little Boost Gets You Over the Finish LineBradford S. Hoppe, MD, MPH, and Omran Saifi, MD, offer a peer perspective on research by Gavin Jones, MD, and colleagues into radiation therapy in diffuse large B-cell lymphoma.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
Between the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal CancerLiliana Bustamante, MD, and Richard Kim, MD, discuss circulating tumor DNA as a potential prognostic biomarker for patients with colorectal cancer.
Latest:
First-Line Treatment OptionsPanelists discuss first-line treatment strategies for metastatic non–clear cell renal cell carcinoma, highlighting the shift from broad, subtype-agnostic approaches to histology-specific and biomarker-driven therapies, including evolving combinations of TKIs and immunotherapy tailored to tumor biology.
Latest:
Disorders of Sex Development and Malignant Germ Cell TumorsKey points: Patients with disorders of sex development (DSDs) are at an increased risk of malignant germ cell tumors (GCTs). In adulthood, the partial form of androgen insensitivity syndrome confers the greatest risk of developing malignant GCTs. Gonadoblastoma is the most common gonadal GCT arising in patients with DSDs. Despite being a benign neoplasm, it can undergo malignant transformation in up to 60% of patients with a DSD. Oncologic treatment in patients with disorders of sex development and malignant GCTs does not differ from the standard treatment for testicular GCTs. Treatment of patients with DSDs requires a multidisciplinary team, including a psychiatric, genetic, and reproductive assessment as well as the involvement of an ethics committee. An early diagnosis of DSDs is crucial to avoid the development of potentially serious complications in adulthood.
Latest:
Oncology Peer Review On-The-Go: Value of Geriatric Assessment in Patients With Genitourinary CarcinomasLead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.
Latest:
Future Perspectives and Unmet Needs in Multiple MyelomaThe expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Latest:
Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.
Latest:
Oncology Peer Review On-The-Go: Cancer Pain and Opioid Use DisorderAuthors Daniel C. McFarland, DO, and Kirk Harris, MD, spoke with CancerNetwork® about their manuscript on cancer pain’s relationship with opioid use disorder that was recently published in the journal ONCOLOGY®.
Latest:
Addressing Resistance to Targeted Therapies in Metastatic Colorectal CancerInvestigators discuss the use of targeted therapies to treat metastatic colorectal cancer.
Latest:
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma TreatmentZenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Latest:
Cevostamab Combo Shows Enduring Responses in R/R Multiple MyelomaAdditional time is necessary to confirm the depth and durability of responses observed in the phase 1 CAMMA 1 study.
